Purpose: The role of peritoneal washing cytology in determining further treatment strategies after surgery for gastric cancer remains unclear. One reason for this is the fact that optimal procedures to increase the accuracy of predicting peritoneal metastasis have not been established. The aim of this study was to evaluate the efficacy of cytology using samples harvested from two different abdominal cavity sites during gastric cancer surgery. Materials and Methods: We prospectively recruited 108 patients who were clinically diagnosed with locally advanced gastric cancer (higher than cT1 stage disease). Peritoneal washing fluids were collected from the pouch of Douglas and the subphrenic area. Patients were prospectively followed up for 2 years to determine the recurrence and survival rates. Results: Thirty-three patients dropped out of the study for various reasons, so 75 patients were included in the final analysis. Seven patients (9.3%) showed positive cytology findings, of whom, three showed peritoneal recurrence. Tumor size was the only factor associated with positive cytology findings (P=0.037). The accuracy and specificity of cytology for predicting peritoneal recurrence were 90.1% and 94.2%, respectively, whereas the sensitivity was 50.0%. The survival rate did not differ between patients with positive cytology findings and those with negative cytology findings (P=0.081). Conclusions: Peritoneal washing cytology using samples harvested from two different sites in the abdominal cavity was not able to predict peritoneal recurrence or survival in gastric cancer patients. Further studies will be required to determine whether peritoneal washing cytology during gastric cancer surgery is a meaningful procedure. Therefore, it is important to prevent peritoneal recurrence after curative surgery to improve the prognosis of gastric cancer patients.
Introduction
Although the incidence of gastric cancer has declined recently, gastric cancer remains one of the most common causes of death due to malignant tumors worldwide. 1 A major cause of gastric cancer-associated mortality in patients who undergo curative resection is recurrent disease, with the most common site of recurrence being the peritoneum. 2 To date, multimodal treatment strategies have been used to improve the prognosis of gastric cancer patients with peritoneal recurrence, but the results remain unsatisfactory. 3 Therefore, it is important to prevent peritoneal recurrence after curative surgery to improve the prognosis of gastric cancer patients.
The recent trend in treatment is the administration of adjuvant intraperitoneal chemotherapy immediately after resection in patients who are at high risk for peritoneal recurrence. 4, 5 However, to apply this modality, selection of patients who are at high risk for peritoneal recurrence is crucial. Although the precise mechanism driving peritoneal recurrence remains unclear, the presence of malignant cells in the peritoneum at the time of surgery can lead to perito-neal recurrence. 6, 7 Therefore, examination of peritoneal fluids has emerged as an option for identifying patients who are at high risk for peritoneal recurrence after curative resection.
Several previous studies have reported that examination of the peritoneum for free malignant cells is effective for predicting peritoneal metastasis from gastric cancer. 8, 9 Moreover, this approach does not require any additional procedures and is non-invasive since it can be performed concurrently with the resection operation. On the basis of these clinical results and because of the ease of performance of the procedure, positive cytology findings are considered to represent distant metastasis according to the gastric cancer classification system proposed by the Japanese Gastric Cancer Association (JGCA). 10 Furthermore, the recent guidelines of the TNM staging system of the American Joint Committee for Cancer (AJCC) also consider positive peritoneal cytology as a sign of metastatic disease. 11 However, cytology is not yet routinely performed during gastric cancer surgery because the reported accuracy and sensitivity of cytology vary, being low in some studies. 12 Therefore, optimal procedures to increase the efficacy and reproducibility of this modality need to be established. To address this issue, we conducted a prospective study with the aim of increasing the efficacy and reproducibility of cytology using washing samples collected from multiple peritoneal sites such as the pouch of Douglas and the upper abdomen.
The aims of this prospective study were to determine the prevalence of positive cytology findings using samples from two peritoneal sites in gastric cancer patients and to investigate the efficacy of cytology in predicting peritoneal recurrence of gastric cancer. On the basis of these results, we sought to determine the necessity of cytology during gastric cancer surgery.
Materials and Methods one or both fluid samples from the two peritoneal sites had suspicious findings or findings that were definitive for malignancy, the sample was considered as being positive for malignancy (Fig. 1) ; all other findings were considered as negative for malignancy. The resected specimens were also examined by the pathologist and were classified according to the AJCC TNM classification (7th edition) 11 and the Japanese Classification of Gastric Carcinoma. 10 5. Follow-up strategy and detection of recurrence 
Study design

Sample size and statistical analysis
The sample size was calculated using G-Power version 3.1. was approximately 10% in a previous report. 9 The proportion of samples with positive cytology findings on using our detection methods (sampling from two different sites) was assumed to be 20%. The type I error was set as 0.1 (one sided) and the power was 90%. The sample size was calculated accordingly considering the use of the chi-square test. A sample size of 108 was required to detect a significant increase in the positive cytology rate in our study compared to the previous report, accounting for a 25% dropout rate.
Statistical analysis was performed using Statistical Package for the Social Sciences (SPSS), version 21 for Mac OS (IBM Corp., Armonk, NY, USA). Categorical data were analyzed using the chisquare test or Fisher's exact test. Survival was assessed using the Kaplan-Meier method and was compared between groups using the log-rank test. A value of P＜0.05 was considered statistically significant.
Results
A total of 108 patients were initially enrolled in the current study. However, 12 patients (11.1%) were subsequently found to have previously undetected metastatic lesions or a non-resectable extension of the primary tumor during surgery. In addition, 15 patients (13.9%) with resectable lesions were found to have earlystage gastric cancer during surgery, and six other patients were lost to follow-up in 1 year or less after surgery, without confirmation of the recurrence status or death. Another 33 patients withdrew from the study, resulting in a total of 75 patients for whom peritoneal washing cytology was finally performed followed by gastric resection with lymph node dissection (Fig. 2 ).
Background characteristics of the patients are listed in Table Survival rates of patients enrolled in the study. Overall survival rate (A) and disease-free survival rate (B) according to cytology results. The P-value was calculated using the log-rank test. Table 2 .
We sought to determine the differences between definitive and suspicious cytology results for malignancy in terms of the accuracy of predicting peritoneal recurrence. When positive results were de- fined as suspicious or definitive results for malignancy, the accuracy was 90.1%. When the criterion was limited to definitive results for malignancy, the accuracy increased slightly to 93.3% (Table 3 ). The sensitivity, specificity, and predictive values of cytology, for assessing its diagnostic value, are listed in Table 3 . In contrast with other metrics, the positive predictive value significantly increased from 42.9% to 75.0% when the criterion for positive cytology findings was limited to definitive results for malignancy.
Discussion
In the present prospective study, we found that cytology was associated with a low sensitivity and positive predictive value for predicting peritoneal recurrence in patients with gastric cancer, despite the fact that we performed cytology using samples collected from findings were detected in only 12% of patients who were pathologically diagnosed with serosa-exposed primary tumors (stage pT4 or higher). 15 Meanwhile, other studies have reported rates of positive cytology findings ranging from 15.7% to 35.0%. 8, [16] [17] [18] These variable rates can be attributed to the pathologic differences among the recruited patients. Patients with primary tumors not involving the serosa had a positive cytology finding rate of 1.0% or less, whereas this rate was 20% or higher among patients with tumors involving the serosa. 8, 9 In our study, the rate of positive cytology findings was relatively low (9.3%) compared to previous reports, despite the fact that we collected samples from multiple sites. Our study was designed as a prospective study, and we therefore attempted to en- According to most previous reports, the sensitivity of cytology for predicting peritoneal recurrence is relatively lower (ranging from 11% to 43%) than the corresponding specificity. 8, 9, 19, 20 This low sensitivity indicates that many patients with negative findings on peritoneal cytology can develop peritoneal recurrence. We collected samples from two different sites to increase the sensitivity of cytology in our study, but the results were disappointing. Of the patients who developed peritoneal recurrence, 50% had negative peritoneal cytology findings. To date, several efforts have been made to increase the sensitivity of cytology for predicting peritoneal recurrence in gastric cancer. Hayes et al. 21 reported that collection of samples for cytology using peritoneal brushing could increase the detection rate of free malignant cells in the peritoneum. In another study, cytology was performed by directly rinsing the surface of the primary tumor with saline. 22 However, this might provoke undesirable exfoliation of tumor cells from the primary tumor involving the serosal surface, which could potentially decrease the specificity due to false-positive results. In our study, we also did not observe a satisfactory sensitivity, despite checking samples from two common sites of peritoneal metastasis: the subphrenic area and the pouch of Douglas.
Another method for improving the sensitivity of cytology in gastric cancer is to check for the presence of molecular markers using immunohistochemistry or reverse transcription polymerase chain reaction (RT-PCR). Immunohistochemical staining with, for example, Ber-EP4 or HEA-125, has been performed to detect free cancer cells in the peritoneum, but this method has also been found Table   2 ). Those with advanced gastric cancer were postoperatively treated and more than 80% of peritoneal recurrences have been reported to be detected within 2 years after surgery, 2,31 we will need to follow up these patients over 5 years to confirm the value of positive cytology findings as a prognostic factor.
Taken together, our findings suggest that peritoneal washing cytology had a low sensitivity for predicting peritoneal recurrence in patients with clinically and surgically determined advanced gastric cancer. Despite using samples collected from two different abdominal cavity sites, the observed rate of positive peritoneal cytology finding was not higher than expected. Moreover, it was not clear from our study whether peritoneal cytology findings are appropriate for predicting prognosis in patients. However, our study did not show the results of long-term follow-up of the recruited patients, and the study sample size was calculated according to the rate of positive findings for malignancy on cytology, instead of according to the significance of survival differences or the differential accuracy of predicting peritoneal recurrence according to cytology results. Therefore, we could not determine whether peritoneal cytology should be completely excluded in gastric cancer surgery.
Further studies with greater numbers of patients or additional molecular analysis could make this procedure more meaningful in the future.
